New York, February 27, 2018:
Plasma Protein Therapeutics Market Forecast 2018
The Plasma Protein Therapeutics Market is expected to exceed more than USD 31 Billion by 2024; Growing at a CAGR of more than 7.5% in the given forecast period.
The scope of the report includes a detailed study of global and regional markets .The reasons given for variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Baxter International, Biotest, CSL Behring, Grifols, S.A., Kedrion, Octapharma USA, Inc., Shire Plc. and China Biologics. CSL Behring is the market leader in the plasma protein therapeutics market, while GRIFOLS, S.A leads the global market for IVIG and Alpha 1 antitrypsin. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
You Can Find Full Report here: https://www.marketresearchengine.com/reportdetails/plasma-protein-therapeutics-market-report
The Plasma Protein Therapeutics Market has been segmented as below:
By Product Type Analysis
C1 esterase Inhibitors
By Application Analysis
Primary Immunodeficiency Disorder
Others (Kawasaki disease, GBS, CIDP etc)
By Regional Analysis
Rest of the World
This report provides:
1) An overview of the global market for plasma protein therapeutics and related technologies.
2) Analyses of global market trends, with data from 2013, estimates for 2014 and 2015, and projections of compound annual growth rates (CAGRs) through 2020.
3) Identifications of new market opportunities and targeted promotional plans for plasma protein therapeutics.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
Request Sample Report: https://www.marketresearchengine.com/reportdetails/plasma-protein-therapeutics-market-report
Table of Contents
2 Research Methodology
3 Global Plasma Protein Therapeutics Market Revenue Analysis, 2014–2024
4 North America Plasma Protein Therapeutics Market Revenue Analysis, 2014–2024
4.1 North America Plasma Protein Therapeutics Market Revenue, By Product Type, 2014–2024 (US$ Mn)
4.1.1 North America Immunoglobulins Market Revenue, 2014–2024 (US$ Mn)
4.1.2 North America Albumin Market Revenue, 2014–2024 (US$ Mn)
4.1.3 North America Coagulation Factors Market Revenue, 2014–2024 (US$ Mn)
4.1.4 North America C1-esterase Inhibitors Market Revenue, 2014–2024 (US$ Mn)
4.2 North America Plasma Protein Therapeutics Market Revenue, By Application, 2014–2024 (US$ Mn)
4.2.1 North America Hemophilia Market Revenue, 2014–2024 (US$ Mn)
4.2.2 North America Primary Immunodeficiency Disorder (PID) Market Revenue, 2014–2024 (US$ Mn)
4.2.3 North America Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2014–2024 (US$ Mn)
4.2.4 North America Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, and Congenital AIDS, etc.) Market Revenue, 2014–2024 (US$ Mn)
4.2.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
4.3 North America Plasma Protein Therapeutics Market Revenue, by Country 2014–2024 (US$ Mn)
5 Europe Plasma Protein Therapeutics Market Revenue, 2014–2024
6 Asia Pacific Plasma Protein Therapeutics Market Revenue Analysis, 2014–2024
7 Latin America Plasma Protein Therapeutics Revenue Analysis, 2014–2024
8 Rest of the World (RoW) Plasma Protein Therapeutics Market Revenue Analysis, 2014–2024
9 Company Profiles
9.1 Baxter International
9.3 CSL Behring
9.4 China Biologics
9.5 GRIFOLS, S.A.
9.7 Octapharma USA, Inc.
9.8 Shire Plc.